Pipeline Insight: HIV

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-04-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In the current antiretroviral landscape, resistance in all three of the established classes is proving to be problematic. Accordingly, current clinical trials are recruiting treatment-resistant patients, and many companies are actively positioning their drugs in later therapy. The emergence of the Entry Inhibitor class is also expected to change the market place.


Scope

  • The changing epidemiology of HIV is discussed, as well as the changing unmet needs that are currently presenting themselves
  • Late-phase clinical trials are examined, with comparators assessed and opinion leader comments on trial design included
  • Forecasted sales of the antiretroviral market in the next 10 years with two possible scenarios relating to a changing treatment paradigm
  • An assessment of the novel Entry Inhibitor class, its implications for future therapy, and its impact upon the seven major markets


    • Report Highlights
    The majority of pipeline products are being developed for the treatment of resistant virus and are expected to be used in second and later lines of therapy. However, disappointing data and uncertain positioning has created a lack of clarity among physicians as to where some late-stage drugs should be used.

    Datamonitor expects the NRTIs to remain the dominant class, contributing 38% of total sales by 2015, although the EIs will experience the most rapid growth. However, should the CCR5 inhibitors be used first-line, in 2015 over a quarter of sales will be accounted for by the EI class, compared to 14% if they are used in salvage therapy.

    Several drugs, such as tipranavir and capravirine, are viewed as ‘holding drugs’ where physicians are likely to use them only until improved alternatives are available. To ensure maximum sales during this limited lifespan, companies should undertake an intensive initial marketing campaign before switching leads to premature sales decrease.


    Reasons to Purchase

  • Understand key drivers in the antiretroviral market and predict the future performance of key compounds
  • Understand the changing unmet needs of patients and clinical endpoints used in current trial design
  • Evaluate scenario-based forecasts of the antiretroviral market in the next 10 years, taking into account patent expiry and generic incursion

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase haart pipeline hiv lifespan bms

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.